Развитие реакции «трансплантат против хозяина» у реципиента печени. Клинические наблюдения и обзор литературы

Реакция «трансплантат против хозяина» (РТПХ) после трансплантации печени (ТП) наблюдается у 0,2–0,3% реципиентов. Каждый случай характеризуется индивидуальными особенностями клинической картины. Не существует стандартов или клинических рекомендаций профессиональных сообществ по лечению РТПХ у реципиентов солидных органов, а летальность этих больных остается очень высокой. Мы представляем два клинических наблюдения верифицированной РТПХ, развившейся в ранние сроки после ТП, и предлагаем краткий обзор современного состояния изучения этой проблемы.

1. Сушков АИ, Малиновская ЮО, Милосердов ИА, Мойсюк ЯГ. Тяжелая иммунная гемолитическая анемия после трансплантации печени. Вестник трансплантологии и искусственных органов. 2013; 15 (2): 109– 112. doi: 10.15825/1995-1191-2013-2-109-112.

2. Burdick JF, Vogelsang GB, Smith WJ, Farmer ER, Bias WB, Kaufmann SH et al. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med. 1988 Mar 17; 318 (11): 689–691.

3. Kim GY, Schmelkin LA, Davis MDP, El-Azhary RA, Farrell AM, Meves A, Lehman JS. Dermatologic manifestations of solid organ transplantation-associated graftversus-host disease: A systematic review. J Am Acad Dermatol. 2018; 78 (6): 1097–1101e1.

4. Akbulut S, Yilmaz M, Yilmaz S. Graft-versus-host disease after liver transplantation: A comprehensive literature review. World J Gastroenterol. 2012; 18 (37): 5240–5248.

5. Murali AR, Chandra S, Stewart Z, Blazar BR, Farooq U, Ince MN, Dunkelberg J. Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management. Transplantation. 2016; 100 (12): 2661–2670.

6. Chesdachai S, Udompap P, Yetmar ZA, Watt KD, Aqel BA, Yang L, Beam E. Infectious complications in acute graft-versus-host disease after liver transplantation. Transpl Infect Dis. 2022; 24 (4): e13843.

7. Kitajima T, Henry M, Ivanics T, Yeddula S, Collins K, Rizzari M et al. Incidence and Risk Factors for Fatal Graft-versus-host Disease After Liver Transplantation. Transplantation. 2021; 105 (12): 2571–2578.

8. Скворцова ЮВ, Олисов ОД, Сюткин ВЕ, Коновалов ДМ, Чжао АВ. Кожная форма реакции «трансплантат против хозяина» у пациентки через 1 год после ортотопической трансплантации печени: описание случая и обзор литературы. Трансплантология. 2010; (1): 61–67. doi: 10.23873/2074-0506-2010-0-1-61-67.

9. Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant. 2004; 4 (4): 466–474.

10. Tian M, Lyu Y, Wang B, Liu C, Yu L, Shi JH et al. Diagnosis and treatment of acute graft-versus-host disease after liver transplantation: Report of six cases. World J Clin Cases. 2021; 9 (30): 9255–9268.

11. Sudhindran S, Taylor A, Delriviere L, Collins VP, Liu L, Taylor CJ et al. Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection. Am J Transplant. 2003; 3 (8): 1024– 1029.

12. Jacobs MT, Olson M, Ferreira BP, Jin R, Hachem R, Byers D et al. The use of ruxolitinib for acute graft-versushost disease developing after solid organ transplantation. Am J Transplant. 2020; 20 (2): 589–592.

13. Auerbach JS, Schott CK. Solid-Organ Graft-Versus-Host Disease After Liver Transplant: A Case Report. Crit Care Nurse. 2016; 36 (3): e7–e11.

14. Elsiesy H, Ibrahim A, Selim K, Al Sebayel M, Broering D, Al Hamoudi W et al. Graft-versus-Host Disease after Liver Transplantation: A Single-Center Case Series. Ann Transplant. 2015; 20: 397–401.

15. Ofosu A, Zabolotsky A, Rufail M, Spataro J, Civan J. Graft-versus-host disease, a rare complication after or thotopic liver transplantation. Clin Case Rep. 2018; 6 (1): 238–239.

16. Qiu W, Lv GY, Jiang C, Zhang P, Sun XD, Shi XJ et al. Successful salvage treatment of acute graft-versus-host disease after liver transplantation by withdrawal of immunosuppression: a case report. Korean J Hepatobiliary Pancreat Surg. 2016; 20 (1): 38–43.

17. Rogulj IM, Deeg J, Lee SJ. Acute graft versus host disease after orthotopic liver transplantation. J Hematol Oncol. 2012; 5: 50.

18. Knox KS, Behnia M, Smith LR, Vance GH, Busk M, Cummings OW et al. Acute graft-versus-host disease of the lung after liver transplantation. Liver Transpl. 2002; 8 (10): 968–971.

19. Massey V, Martel V, Nguyen DK, Busque L, Chapdelaine H, Keezer MR. Acute central nervous system graftversus-host-disease after liver transplantation. Transpl Immunol. 2022; 70: 101521.

20. Kreft A, Hippe K, Wagner-Drouet EM, Ries I, Kandulski A, Büttner-Herold M et al. An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host disease. PloS One. 2021; 16 (8): e0256543.

21. Wegner J, Weidenthaler-Barth B, Engelbert J, Knothe M, Braun C, Helbig D et al. Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease. Exp Dermatol. 2021; 30 (12): 1814–1819.

22. Perri R, Assi M, Talwalkar J, Heimbach J, Hogan W, Moore SB, Rosen CB. Graft vs host disease after liver transplantation: a new approach is needed. Liver Transpl. 2007; 13 (8): 1092–1099.

23. Schulman JM, Yoon C, Schwarz J, Vagefi PA, Mully TW, Shinkai K. Absence of peripheral blood chimerism in graft-vs-host disease following orthotopic liver transplantation: case report and review of the literature. Int J Dermatol. 2014; 53 (11): e492–498.

24. Chinnakotla S, Smith DM, Domiati-Saad R, Agura ED, Watkins DL, Netto G et al. Acute graft-versus-host disease after liver transplantation: role of withdrawal of immunosuppression in therapeutic management. Liver Transpl. 2007; 13 (1): 157–161.

25. Zhang MY, Zhao P, Zhang Y, Wang JS. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. PloS One. 2022; 17 (7): e0271979.

26. Ricordi C, Tzakis AG, Zeevi A, Rybka WB, Demetris AJ, Fontes PA et al. Reversal of graft-versus-host disease with infusion of autologous bone marrow. Cell Transplant. 1994; 3 (2): 187–192.

27. Kuball J, Theobald M, Ferreira EA, Hess G, Burg J, Maccagno G et al. Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation. 2004; 78 (12): 1774–1779.

28. Cooper JP, Abkowitz JL. How I diagnose and treat acute graft-versus-host disease after solid organ transplantation. Blood. 2023 Mar 9; 141 (10): 1136–1146.

29. Kim SJ, Park S, Rhu J, Kim JM, Choi GS, Joh JW. The clinical impact of donor against recipient HLA one way mismatch on the occurrence of graft versus host disease in liver transplantation. Sci Rep. 2022; 12 (1): 20337.

30. Hiwarkar P, Shaw BE, Tredger JM, Brown NW, Kulkarni S, Saso R et al. Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. Clin Transplant. 2011; 25 (2): 222–227.

31. Patra S, Vij M, Sukanya B, Kapoor D. Mycophenolate mofetil-induced colitis with graft versus host diseaselike features in a liver transplant recipient. Indian J Pathol Microbiol. 2012; 55 (4): 506–508.

32. Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol. 2003; 11 (4): 295–302.